India Czech Republic covid-19 innovations vaccine malaria India Czech Republic

Novavax buys Praha Vaccines for Covid-19 vaccine manufacturing

Reading now: 854
www.pharmaceutical-technology.com

Biotechnology firm Novavax has acquired Czech Republic-based Praha Vaccines for approximately $167m to support the manufacture of its Covid-19 vaccine candidate, NVX‑CoV2373.

The acquisition covers a 150,000ft2 vaccine and biologics manufacturing facility and related assets in Bohumil, Czech Republic, as well as the existing employees along with all associated and necessary infrastructure.

Novavax estimates that the manufacturing facility will enable an annual capacity of more than one billion doses of antigen, from next year, for its Covid-19 vaccine candidate.

Praha Vaccines is a subsidiary of the Cyrus Poonawalla Group, the parent company of Serum Institute of India focused on manufacturing immuno-biologicals.

Read more on pharmaceutical-technology.com
The website covid-19.rehab is an aggregator of news from open sources. The source is indicated at the beginning and at the end of the announcement. You can send a complaint on the news if you find it unreliable.

Related News

DMCA